Signaling via the CXCR5/ERK pathway is mediated by CXCL13 in mice with breast cancer

Xu,Licheng; Liang,Zhi; Li,Shuyan; Ma,Jianjun

doi:10.3892/ol.2018.8510

Signaling via the CXCR5/ERK pathway is mediated by CXCL13 in mice with breast cancer

Authors:
- Licheng Xu
- Zhi Liang
- Shuyan Li
- Jianjun Ma
View Affiliations

Affiliations: Department of Breast Surgery, Yantaishan Hospital, Yantai, Shandong 264002, P.R. China, Department of Medical Oncology, The People's Liberation Army 107th Hospital, Yantai, Shandong 264002, P.R. China
Published online on: April 17, 2018 https://doi.org/10.3892/ol.2018.8510
Pages: 9293-9298

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Breast cancer is the most common cause of cancer‑associated mortality and the most frequently diagnosed type of cancer in women worldwide. It has been revealed that the chemokine C‑X‑C motif chemokine ligand 13 (CXCL13) serves a pivotal role in breast cancer growth and is associated with lymph node metastasis. However, to the best of our knowledge, the mechanism by which CXCL13 mediates breast cancer growth remains uncharacterized. Female BALB/c mice were used in this study. Tumor volume was calculated and changes of gross tumor morphology were observed by hematoxylin and eosin staining. The expression of CXCL13, C‑X‑C motif chemokine receptor 5 (CXCR5) and extracellular signaling‑related kinase (ERK) mRNA and protein expression were detected by reverse transcriptase quantitative‑polymerase chain reaction and western blot analysis. Simultaneously, the production of cytokines [interleukin‑1β (IL‑1β), tumor necrosis factor (TNF) and tumor growth factor β1 (TGF‑β1)] was detected by an ELISA. The CXCL13 inhibitor reduced tumor volume and growth, and reduced the mRNA and protein expression levels of key members of the CXCR5/ERK signaling pathway: CXCL13, CXCR5 and ERK. Furthermore, the detectable concentration of the cytokines IL‑1β and TNF decreased following CXCL13 inhibition, whereas the concentration of TGF‑β1 was increased. The attenuation of tumor growth resulting from CXCL13 inhibition may be associated with the CXCR5/ERK signaling pathway. This study provides a theoretical basis for treating breast cancer through CXCL13 inhibition in clinical trials.

View Figures

View References

1	Soria G, Ofri-Shahak M, Haas I, Yaal-Hahoshen N, Leider-Trejo L, Leibovich-Rivkin T, Weitzenfeld P, Meshel T, Shabtai E, Gutman M and Ben-Baruch A: Inflammatory mediators in breast cancer: Coordinated expression of TNF-α & IL-1β with CCL2 & CCL5 and effects on epithelial-to-mesenchymal transition. BMC Cancer. 11:1302011. View Article : Google Scholar : PubMed/NCBI
2	Wang F, Li L, Chen Z, Zhu M and Gu Y: MicroRNA-214 acts as a potential oncogene in breast cancer by targeting the PTEN-PI3K/Akt signaling pathway. Int J Mol Med. 37:1421–1428. 2016. View Article : Google Scholar : PubMed/NCBI
3	Dauksa A, Jakstaitė A, Gasianec A and Dambrauskas Z: Loss of proapoptotic gene Apaf-1 expression in pancreatic cancer. Health Sci. 25:9–12. 2015. View Article : Google Scholar
4	Li Y, Zheng Y, Li T, Wang Q, Qian J, Lu Y, Zhang M, Bi E, Yang M, Reu F, Yi Q and Cai Z: Chemokines CCL2, 3, 14 stimulate macrophage bone marrow homing, proliferation and polarization in multiple myeloma. Oncotarget. 6:24218–24229. 2015.PubMed/NCBI
5	Tan KW, Evrard M, Tham M, Hong M, Huang C, Kato M, Prevost-Blondel A, Donnadieu E, Ng LG and Abastado JP: Tumor stroma and chemokines control T-cell migration into melanoma following Temozolomide treatment. Oncoimmunology. 4:e9787092015. View Article : Google Scholar : PubMed/NCBI
6	Bryant VL and Slade CA: Chemokines, their receptors and human disease: The good, the bad and the itchy. Immunol Cell Biol. 93:364–371. 2015. View Article : Google Scholar : PubMed/NCBI
7	Li Y, Wang W, Tang L, He X, Yan X, Zhang X, Zhu Y, Sun J, Shi Y, Ma X, et al: Chemokine (C-X-C motif) ligand 13 promotes intrahepatic chemokine (C-X-C motif) receptor 5+ lymphocyte homing and aberrant B-cell immune responses in primary biliary cirrhosis. Hepatology. 61:1998–2007. 2015. View Article : Google Scholar : PubMed/NCBI
8	Biswas S, Sengupta S, Chowdhury Roy S, Jana S, Mandal G, Mandal PK, Saha N, Malhotra V, Gupta A, Kuprash DV and Bhattacharyya A: CXCL13-CXCR5 co-expression regulates epithelial to mesenchymal transition of breast cancer cells during lymph node metastasis. Breast Cancer Res Treat. 143:265–276. 2014. View Article : Google Scholar : PubMed/NCBI
9	Chen L, Huang Z, Yao G, Lyu X, Li J, Hu X, Cai Y, Li W, Li X and Ye C: The expression of CXCL13 and its relation to unfavorable clinical characteristics in young breast cancer. J Transl Med. 13:1682015. View Article : Google Scholar : PubMed/NCBI
10	Panse J, Friedrichs K, Marx A, Hildebrandt Y, Luetkens T, Barrels K, Horn C, Stahl T, Cao Y, Milde-Langosch K, et al: Chemokine CXCL13 is overexpressed in the tumour tissue and in the peripheral blood of breast cancer patients. Br J Cancer. 99:930–938. 2008. View Article : Google Scholar : PubMed/NCBI
11	Chen L, Huang Z, Yao G, Lyu X, Li J, Hu X, Cai Y, Li W, Ye C and Li X: Erratum to: The expression of CXCL13 and its relation to unfavorable clinical characteristics in young breast cancer. J Transl Med. 14:3182016. View Article : Google Scholar : PubMed/NCBI
12	Dorsam RT and Gutkind JS: G-protein-coupled receptors and cancer. Nat Rev Cancer. 7:79–94. 2007. View Article : Google Scholar : PubMed/NCBI
13	del Molino del Barrio I, Kirby J and Ali S: The role of chemokine and glycosaminoglycan interaction in chemokine-mediated migration in vitro and in vivo. Methods Enzymol. 570:309–333. 2016. View Article : Google Scholar : PubMed/NCBI
14	Meijer J, Zeelenberg IS, Sipos B and Roos E: The CXCR5 chemokine receptor is expressed by carcinoma cells and promotes growth of colon carcinoma in the liver. Cancer Res. 66:9576–9582. 2006. View Article : Google Scholar : PubMed/NCBI
15	Zhu Z, Zhang X, Guo H, Fu L, Pan G and Sun Y: CXCL13-CXCR5 axis promotes the growth and invasion of colon cancer cells via PI3K/AKT pathway. Mol Cell Biochem. 400:287–295. 2015. View Article : Google Scholar : PubMed/NCBI
16	Wu W, Qian L, Chen X and Ding B: Prognostic significance of CXCL12, CXCR4 and CXCR7 in patients with breast cancer. Int J Clin Exp Pathol. 8:13217–13224. 2015.PubMed/NCBI
17	Panse J, Friedrichs K, Marx A, Hildebrandt Y, Luetkens T, Bartels K, Horn C, Stahl T, Cao Y, Milde-Langosch K, et al: Chemokine CXCL13 is overexpressed in the tumour tissue and in the peripheral blood of breast cancer patients. Br J Cancer. 99:930–938. 2008. View Article : Google Scholar : PubMed/NCBI
18	Lobenhofer EK, Huper G, Iglehart JD and Marks JR: Inhibition of mitogen-activated protein kinase and phosphatidylinositol 3-kinase activity in MCF-7 cells prevents estrogen-induced mitogenesis. Cell Growth Differ. 11:99–110. 2000.PubMed/NCBI
19	Bosch A, Li Z, Bergamaschi A, Ellis H, Toska E, Prat A, Tao JJ, Spratt DE, Viola-Villegas NT, Castel P, et al: PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer. Sci Transl Med. 7:283ra512015. View Article : Google Scholar : PubMed/NCBI
20	Hindley A and Kolch W: Extracellular signal regulated kinase (ERK)/mitogen activated protein kinase (MAPK)-independent functions of Raf kinases. J Cell Sci. 115:1575–1581. 2002.PubMed/NCBI
21	Tran DD, Koch A, Saran S, Armbrecht M, Ewald F, Koch M, Wahlicht T, Wirth D, Braun A, Nashan B, et al: Extracellular-signal regulated kinase (Erk1/2), mitogen-activated protein kinase-activated protein kinase 2 (MK2) and tristetraprolin (TTP) comprehensively regulate injury-induced immediate early gene (IEG) response in in vitro liver organ culture. Cell Signal. 28:438–447. 2016. View Article : Google Scholar : PubMed/NCBI
22	Liu S, Uppal H, Demaria M, Desprez PY, Campisi J and Kapahi P: Simvastatin suppresses breast cancer cell proliferation induced by senescent cells. Sci Rep. 5:178952015. View Article : Google Scholar : PubMed/NCBI
23	Zhang Q, Cao DL, Zhang ZJ, Jiang BC and Gao YJ: Chemokine CXCL13 mediates orofacial neuropathic pain via CXCR5/ERK pathway in the trigeminal ganglion of mice. J Neuroinflammation. 13:1832016. View Article : Google Scholar : PubMed/NCBI
24	Milde-Langosch K, Bamberger AM, Rieck G, Grund D, Hemminger G, Müller V and Löning T: Expression and prognostic relevance of activated extracellular-regulated kinases (ERK1/2) in breast cancer. Br J Cancer. 92:2206–2215. 2005. View Article : Google Scholar : PubMed/NCBI
25	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
26	Soria G and Benbaruch A: The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer Lett. 267:271–285. 2008. View Article : Google Scholar : PubMed/NCBI
27	Aravindan BK, Prabhakar J, Somanathan T and Subhadra L: The role of chemokine receptor 4 and its ligand stromal cell derived factor 1 in breast cancer. Ann Transl Med. 3:232015.PubMed/NCBI
28	Kitamura T and Pollard JW: Therapeutic potential of chemokine signal inhibition for metastatic breast cancer. Pharmacol Res. 100:266–270. 2015. View Article : Google Scholar : PubMed/NCBI
29	Kudirka JC, Panupinthu N, Tesseyman MA, Dixon SJ and Bernier SM: P2Y nucleotide receptor signaling through MAPK/ERK is regulated by extracellular matrix: Involvement of beta3 integrins. J Cell Physiol. 213:54–64. 2007. View Article : Google Scholar : PubMed/NCBI
30	Zhang X, Ma L, Qi J, Shan H, Yu W and Gu Y: MAPK/ERK signaling pathway-induced hyper-O-GlcNAcylation enhances cancer malignancy. Mol Cell Biochem. 410:101–110. 2015. View Article : Google Scholar : PubMed/NCBI
31	Lepen Pleić I, Secombes CJ, Bird S and Mladineo I: Characterization of three pro-inflammatory cytokines, TNFα1, TNFα2 and IL-1β, in cage-reared Atlantic bluefin tuna Thunnus thynnus. Fish Shellfish Immunol. 36:98–112. 2014. View Article : Google Scholar : PubMed/NCBI